Trilipix Dosage/Direction for Use

Patients should be placed on an appropriate lipid-lowering diet before receiving Trilipix as monotherapy or co-administered with a statin and should continue this diet during treatment.
Trilipix modified-release capsules can be taken without regard to meals. Serum lipids should be monitored periodically.
Maximum Dose: 135 mg once daily.
Adults: Co-Administration with Statins for the Treatment of Mixed Dyslipidemia: Trilipix 135 mg may be co-administered with an HMG-CoA reductase inhibitor (statin) in patients with mixed dyslipidemia. For convenience, the daily dose of Trilipix may be taken at the same time as a statin, according to the dosing recommendations for each medication. Co-administration with the maximum dose of a statin has not been evaluated in clinical studies and should be avoided unless the benefits are expected to outweigh the risks.
Severe Hypertriglyceridemia: Initially 45-135 mg once daily. Dosage should be individualized according to patient response and should be adjusted, if necessary, following repeat lipid determinations at 4-8 week intervals. Maximum Dose: 135 mg once daily.
Primary Hyperlipidemia or Mixed Dyslipidemia: 135 mg once daily.
Elderly: Dose selection for the elderly should be made on the basis of renal function.
Renal Impairment: Treatment with Trilipix should be initiated at a dose of 45 mg once daily in patients with mild to moderate renal impairment [creatinine clearance (CrCl) 30-80 mL/min] and should only be increased after evaluation of the effects on renal function and lipid levels at this dose. The use of Trilipix should be avoided in patients with severely impaired renal function.
Hepatic Impairment: Patients with hepatic disease have not been studied.